| 词条 | Hexavalent vaccine |
| 释义 |
| Verifiedfields = | verifiedrevid = | type = combo | component1 = DTaP vaccine | component2 = Hepatitis B vaccine | component3 = Polio vaccine | component4 = Haemophilus vaccine | class1 = Vaccine | class2 = Vaccine | class3 = Vaccine | class4 = Vaccine | tradename = Infanrix hexa, Hexyon, Vaxelis, Hexaxim, EasySix | routes_of_administration = Intramuscular injection | ChemSpiderID_Ref = | ChemSpiderID = none | ATC_prefix = J07 | ATC_suffix = CA09 |drug_name=|image=|alt=|caption=|MedlinePlus=|legal_status=|licence_EU=|pregnancy_AU=|pregnancy_US=|pregnancy_category=|licence_US=|DrugBank=}} A hexavalent vaccine, or 6-in-1 vaccine, is a combination vaccine with six individual vaccines conjugated into one, intended to protect people from multiple diseases. The principal example is a pediatric vaccine, used in more than 90 countries around the world including in Europe, Canada, Australia, and New Zealand[1][2] that protects against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus B, and hepatitis B. FormulationsThe generic vaccine is known as diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant) and haemophilus influenzae type B conjugate vaccine. The liquid vaccine is also known in abbreviated form as DTaP-HepB-IPV-Hib or DTPa-HepB-IPV-Hib. Branded formulations have included Hexavac[3], Hexaxim[4], Hexyon,[5] and Vaxelis[6] manufactured by Sanofi Pasteur, and EasySix manufactured by Panacea Biotec. There is a two-part formulation known in abbreviated form as DTaP-IPV-HepB/Hib or DTPa-HBV-IPV/Hib. It consists of a suspension of diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliomyelitis (DTaP-IPV-HepB or DTPa-HBV-IPV) vaccine that is used to reconstitute a lyophilised (freeze-dried) Haemophilus influenzae type B (Hib) powder. A branded formulation with a 3-antigen pertussis component, Infanrix hexa,[7] is manufactured by GlaxoSmithKline. EU approvalOn 23 October 2000, the European Commission issued marketing approval for Hexavac[8] and Infanrix hexa[9] in the EU. Marketing approval for Hexavac was suspended in November 2005 on the advice of the agency's Committee for Medicinal Products for Human Use (CHMP) in view of the variability of its long-term protection against hepatitis B.[10] In April 2012, the manufacturer Sanofi Pasteur voluntarily withdrew the product from the market. The European Commission formally withdrew marketing permission on 28 June 2012.[8] On 21 June 2012, the EMA issued a positive scientific opinion on Hexaxim for use outside the EU, in cooperation with the WHO.[11] On 17 April 2013, marketing approval in the EU was granted to Hexyon.[12] On 15 February 2016, marketing approval in the EU was granted to Vaxelis.[13] USA approvalNo hexavalent vaccines currently have marketing approval in the USA.[14] References1. ^{{cite journal|title=New perspectives for hexavalent vaccines|first=Pablo|last=Obando-Pacheco||display-authors=etal|doi=10.1016/j.vaccine.2017.06.063|journal=Vaccine|year=2017}} 2. ^{{cite web|url=http://vk.ovg.ox.ac.uk/6-in-1-vaccine|access-date=3 July 2018|date=29 June 2018|title=6-in-1 Vaccine|website=Vaccine Knowledge Group}} 3. ^{{cite web|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000298/human_med_000819.jsp&mid=WC0b01ac058001d124|title=Hexavac|access-date=28 June 2018|website=European Medicines Agency}} 4. ^{{cite web|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/document_listing/document_listing_000352.jsp&mid=|title=Hexaxim H-W-2495|access-date=28 June 2018|website=European Medicines Agency}} 5. ^{{cite web|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002796/human_med_001641.jsp&mid=WC0b01ac058001d124|title=Hexyon|access-date=28 June 2018|website=European Medicines Agency}} 6. ^{{cite web|url=http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/003982/human_med_001962.jsp|title=Vaxelis|access-date=28 June 2018|website=European Medicines Agency}} 7. ^{{cite web|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000296/human_med_000833.jsp&mid=WC0b01ac058001d124|title=Infanrix hexa|website=European Medicines Agency|access-date=28 June 2018}} 8. ^1 {{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2012/08/WC500130968.pdf|title=Public statement on Hexavac. Withdrawal of marketing authorisation in the European Union|access-date=28 June 2018|date=24 July 2012|website=European Medicines Agency}} 9. ^{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000296/WC500032499.pdf|title=EPAR summary for the public: Infanrix hexa|website=European Medicines Agency|access-date=28 June 2018|date=29 November 2017}} 10. ^{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Conclusion/human/000298/WC500074684.pdf|date=16 August 2012|access-date=28 June 2018|website=European Medicines Agency|title=Scientific conclusions and grounds for the suspension of the marketing authorisation of Hexavac presented by the EMEA}} 11. ^{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_for_use_outside_EU/2012/12/WC500135726.pdf|website=European Medicines Agency|access-date=28 June 2018|date=14 June 2016|title=EPAR summary for the public: Hexaxim}} 12. ^{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002796/WC500145761.pdf|title=EPAR summary for the public: Hexyon|access-date=28 June 2018|date=6 July 2017|website=European Medicines Agency}} 13. ^{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003982/WC500202438.pdf|title=EPAR summary for the public: Vaxelis|access-date=28 June 2018|date=26 February 2016|website=European Medicines Agency}} 14. ^{{cite web|url=https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm093833.htm|access-date=28 June 2018|title=Vaccines Licensed for Use in the United States|website=U.S. Food and Drug Administration}} External links{{portal|Pharmacy and pharmacology}}
8 : Vaccines|Combination vaccines|Diphtheria|Tetanus|Pertussis|Polio|Haemophilus|Hepatitis B |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。